Personalized dosing Target opportunities around their core capability of combining prescription drugs with software for personalized dose optimization, offering partnerships with pharma or payers to deliver precision dosing platforms for chronic disease management.

Precision care platform Position as a collaboration hub for biopharma companies seeking to integrate digital health experiences, closed loop care models, and data analytics to enhance therapeutic outcomes and patient adherence.

Leadership momentum Leverage recent executive appointments and strategic hires to approach with joint development or commercialization discussions, highlighting a growing go-to-market capability and board expertise.

Early stage traction Capitalize on milestones such as the GLP-1 dosing platform launch to propose pilots with clinics, health systems, or insurers aiming to improve GLP-1 therapy outcomes and optimize dosing at scale.

Tech-enabled care Highlight their cloud-centric tech stack and digital platforms as a selling point for integrations with existing EHRs, patient apps, and data infrastructures to accelerate adoption and reduce integration risk.